Home / Market News / $GH
benzinga Corporate Catalyst Impact 65/100 ● positive

Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH

Oct 8, 2026, 8:14 PM UTC · Primary ticker $GH

Guardant Health announced European approval for its Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH. This expands the diagnostic's market reach in major global geographies, potentially increasing Guardant Health's revenue and solidifying its position in the oncology diagnostics market.

Guardant Health has received European approval for its Guardant360 CDx, enabling it to be used as a companion diagnostic for AstraZeneca's ETCAMAH. This is a significant development for Guardant Health as it expands the commercial reach of a key product into major global markets, potentially boosting revenue and market share in the oncology diagnostics space. For AstraZeneca, this approval supports the broader adoption and efficacy of its drug ETCAMAH by providing a crucial diagnostic tool. In the short term, this could lead to increased sales for Guardant Health and potentially for AstraZeneca's drug. Long-term, it solidifies Guardant Health's position as a leader in precision oncology diagnostics and enhances its partnership with a major pharmaceutical company, presenting an opportunity for traders to consider Guardant Health's growth trajectory.

$GH positive Expanded market approval for key product
$AZN positive Companion diagnostic approval supports drug sales
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.